Hosted by IDTechEx
Global Biotechnology Insights
Posted on May 13, 2020 by  & 

Trial of Bioelectronic Platform in Rheumatoid Arthritis Patients

SetPoint Medical, a clinical-stage bioelectronic medicine company developing therapy for chronic autoimmune diseases, has received Investigational Device Exemption approval from the US Food and Drug Administration (FDA) to study its proprietary bioelectronic platform in patients with rheumatoid arthritis.
 
The multicenter, double-blind, randomized, sham controlled pivotal trial will enroll up to 250 patients at 40 sites across the US. The trial will evaluate the safety and effectiveness of the SetPoint bioelectronic platform in patients with moderate-to-severe rheumatoid arthritis who are incomplete responders or are intolerant to biologic or targeted synthetic disease modifying anti-rheumatic drugs. for more information see the IDTechEx report on Bioelectronic Medicine 2019-2029.
 
"Rheumatoid arthritis is a debilitating condition for patients, which without effective treatment, can result in long-term loss of physical function and irreversible joint damage," said Jeff Curtis, MD, Professor of Medicine in the Division of Clinical Immunology and Rheumatology at the University of Alabama at Birmingham, and National Co-Principal Investigator. "The results of prior studies suggest that the SetPoint platform is well tolerated and reduces RA signs and symptoms in patients who have had inadequate response to biologic drugs. We look forward to evaluating this promising therapy in a larger blinded study."
 
 
"We are pleased to have received IDE approval and look forward to initiating our pivotal study with our novel platform," said Murthy V. Simhambhatla, PhD, President and CEO of SetPoint Medical. "This is a significant milestone for our company as we work to advance our therapy in patients with RA and other autoimmune diseases, as a potentially efficacious, yet less immunosuppressive option."
 
SetPoint Medical's bioelectronic medicine platform is intended to offer patients and providers a treatment alternative for rheumatoid arthritis, inflammatory bowel disease and other chronic autoimmune conditions with potentially less risk and cost than drug therapy. The company is developing a novel bioelectronic medicine platform that stimulates the vagus nerve to activate the inflammatory reflex to produce a systemic immune-restorative effect.
 
Source and top image: SetPoint Medical
Learn more at the next leading event on the topic: Healthcare Sensor Innovations USA 2020 External Link on 18 - 19 Nov 2020 at Santa Clara Convention Center, CA, USA hosted by IDTechEx.
More IDTechEx Journals